Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Richard Blumberg
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Syntimmune, Inc.
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The research seeks to determine how FcRn affects the outcome of IgG immune-complex responses and association with intestinal inflammation, mainly by defining the relevant signaling pathways and demonstrating that FcRn regulates CD32A associated with IBD in humans. Syntimmune is developing drugs to block the human FcRn receptor modulating IgG-related inflammation. Because the research will increase the “understanding of FcRn function within [antigen presenting cells] in coordinating mucosal immune responses and how they cooperate with FcγR and in so doing broadly extend the implications of FcRn function.”
Intestinal Immune Regulation by IgG and FcRn
PROJECT NARRATIVE The proposed research is relevant to public health because understanding how FcRn coordinates immune re- sponses to IgG at mucosal sites, which in turn regulates activation of the innate and adaptive branches of the immune system, will provide new insights into the mechanisms that either maintain mucosal homeostasis or drive active inflammatory responses and neoplasia. The proposed studies are relevant to the mission of the NIDDK because they are expected to identify new therapeutic strategies for inhibiting inflammation associated with inflammatory bowel disease and providing insights into the genotypic variation associated with this.
Filed on October 18, 2017.
Tell us what you know about Richard Blumberg's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Richard Blumberg filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Richard Blumberg | Brigham and Women's Hospital | Conflict of Interest | Syntalogic | Value cannot be readily determined |
| Richard Blumberg | Brigham and Women's Hospital | Conflict of Interest | Syntimmune, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.